Spyre Therapeutics, Inc. $SYRE Shares Acquired by HighVista Strategies LLC

HighVista Strategies LLC grew its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 91.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 215,746 shares of the company’s stock after acquiring an additional 102,941 shares during the quarter. HighVista Strategies LLC owned about 0.28% of Spyre Therapeutics worth $3,616,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Wellington Management Group LLP increased its stake in Spyre Therapeutics by 8.4% during the 3rd quarter. Wellington Management Group LLP now owns 1,640,312 shares of the company’s stock valued at $27,492,000 after purchasing an additional 126,834 shares in the last quarter. Jefferies Financial Group Inc. raised its stake in Spyre Therapeutics by 11.2% in the 2nd quarter. Jefferies Financial Group Inc. now owns 1,388,854 shares of the company’s stock worth $20,791,000 after acquiring an additional 140,000 shares during the last quarter. Geode Capital Management LLC lifted its position in Spyre Therapeutics by 15.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,227,232 shares of the company’s stock worth $18,373,000 after acquiring an additional 167,669 shares during the period. Baker BROS. Advisors LP grew its stake in Spyre Therapeutics by 59.6% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,000,000 shares of the company’s stock valued at $16,760,000 after purchasing an additional 373,297 shares during the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Spyre Therapeutics by 4.6% in the second quarter. Franklin Resources Inc. now owns 795,275 shares of the company’s stock valued at $11,905,000 after purchasing an additional 34,647 shares during the period. 80.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Leerink Partners upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a report on Thursday, February 19th. Mizuho raised Spyre Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Wells Fargo & Company lifted their price target on Spyre Therapeutics from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. BTIG Research reaffirmed a “buy” rating and set a $70.00 target price on shares of Spyre Therapeutics in a report on Friday, February 20th. Finally, Citigroup began coverage on shares of Spyre Therapeutics in a report on Wednesday, December 17th. They issued a “buy” rating and a $64.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $53.44.

Spyre Therapeutics Trading Down 1.3%

Shares of Spyre Therapeutics stock opened at $39.89 on Monday. Spyre Therapeutics, Inc. has a twelve month low of $10.91 and a twelve month high of $45.76. The firm has a market capitalization of $3.13 billion, a PE ratio of -19.18 and a beta of 3.08. The firm’s 50-day moving average price is $36.06 and its 200 day moving average price is $28.09.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.04). On average, sell-side analysts predict that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Insider Buying and Selling at Spyre Therapeutics

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $32.80, for a total value of $492,000.00. Following the transaction, the chief executive officer owned 657,540 shares in the company, valued at approximately $21,567,312. This trade represents a 2.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Scott L. Burrows sold 2,500 shares of Spyre Therapeutics stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $40.65, for a total transaction of $101,625.00. Following the sale, the chief financial officer directly owned 97,994 shares in the company, valued at approximately $3,983,456.10. This trade represents a 2.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 47,500 shares of company stock valued at $1,686,675. 6.20% of the stock is owned by corporate insiders.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.